Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion

Trial Profile

A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Branch retinal vein occlusion
  • Focus Registrational; Therapeutic Use
  • Acronyms VIBRANT
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2015 According to a Regeneron Pharmaceuticals media release, Aflibercept received approval in Japan by the MHLW for the treatment of patients with macular edema secondary to retinal vein occlusion based on results of this study.
    • 26 Jun 2015 Results published in Santen Pharmaceutical media release.
    • 23 Jan 2015 According to a Regeneron Pharmaceuticals media release, aflibercept has been recommended for approval by the European CHMP for the treatment of visual impairment due to macular oedema secondary to central or branch retinal vein occlusion based on the results of this and another trial (see CT profile 700238571).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top